筋萎縮性側索硬化症治療市場：治療、タイプ、治療ステージ、投与経路、流通チャネル別-2025～2030年の世界予測

筋萎縮性側索硬化症治療市場は、2024年には6億8,806万米ドルとなり、2025年には7億3,306万米ドル、CAGR6.89%で成長し、2030年には10億2,661万米ドルに達すると予測されています。

進化する筋萎縮性側索硬化症治療の世界では、臨床革新と患者ニーズの変化がダイナミックに絡み合っています。近年、筋萎縮性側索硬化症の複雑な病態を理解するために大きな前進がありました。現在進行中の研究開発は、質の高い生活の期間を延長させるだけでなく、治療的介入に対する全体的なアプローチを見直すきっかけとなっています。患者の転帰を改善し、疾病の負担を軽減することに焦点を当て、診断能力と治療方法が同時に進歩するにつれて、市場は成長を続けています。

本レポートでは、治療パラダイムを再定義しつつある新たな動向、技術的ブレークスルー、戦略的な市場の動きを包括的に評価します。最新のデータと強固な分析フレームワークを活用することで、臨床医、調査研究者、意思決定者の視点を統合した議論を展開しています。最終的には、筋萎縮性側索硬化症との継続的な闘いにおける革新と協力的努力の重要性を強調する詳細な図式が展開されます。

筋萎縮性側索硬化症治療市場の変革

近年、筋萎縮性側索硬化症の治療において、従来のパラダイムを覆すような変化が起きています。医薬品と治療の両アプローチにおける革新が急速な進化の時期を引き起こし、新規化合物や前衛的なプロトコールが現状に課題しています。遺伝子治療と幹細胞研究のブレークスルーは、オーダーメイドの治療レジメンへの道を開きつつあり、一方、薬剤製剤の改良は、既存の薬剤の有効性と安全性プロファイルを向上させています。

技術の進歩は、臨床検査や薬事承認が行われるペースを加速させ、発見から患者へのアクセスまでのギャップを効果的に縮めています。さらに、リアルワールドエビデンスとデジタルモニタリング技術が治療戦略を形成し始め、臨床転帰に関する実用的な洞察を提供しています。こうした変革的なシフトは、リスクを受け入れ、先駆的な治療に投資しようという主要利害関係者の意欲の高まりに支えられています。このようなダイナミックな環境は、イノベーションの文化を促進するだけでなく、バリューチェーン全体におけるパートナーシップを強化し、最終的には個別化医療がALSの管理において中心的な役割を果たす未来への舞台を整えています。

ALS治療における主要セグメンテーション洞察

市場セグメンテーションを深く掘り下げると、ALS治療のエコシステムを牽引する多様なビジネス機会が見えてくる。治療別セグメンテーションでは、薬剤療法と治療という2つの主要なアプローチが強調されています。薬剤療法では、デキストロメトルファン/キニジン、エダラボン、リルゾール、Tofersenといった特定の化合物が分析対象となり、それぞれがユニークな作用メカニズムを提供しています。一方、治療動向は遺伝子治療と幹細胞治療にさらに細分化され、疾患の遺伝的基盤を標的とする革新的な解決策への傾向を反映しています。

さらに、ALSのタイプ別に分類すると、家族性ALSと散発性ALSが区別され、治療反応性と臨床戦略の違いが浮き彫りになります。治療段階のセグメンテーションにより、初期、中期、進行期の治療スペクトルが示され、これにより治療介入と疾患進行のより良い調整が可能となります。投与経路（髄腔内投与、静脈内投与、経口投与など）による分析では、患者固有のニーズや臨床環境に対する治療の適応を示します。最後に、病院薬局と小売薬局という切り口から見た流通チャネルに関する洞察は、これらの重要な治療への患者のアクセスを合理化するサプライチェーンマネジメントにおける戦略の進化を強調しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 筋萎縮性側索硬化症の有病率と発症率の増加
    • 効果的なALS治療の潜在的な手段として遺伝子治療と再生医療への注目が高まる
    • 専門的なALS治療センターと支援的な医療インフラの設立の増加
  • 抑制要因
    • ALS治療における治療効果の限界に関する懸念
  • 機会
    • より迅速な評価とより良い患者転帰をサポートする臨床検査ネットワークの拡大
    • ALS治療の調査活動を支援する官民の機関
  • 課題
    • ALS治療の厳格な承認プロセス
• 市場セグメンテーション分析
  • 治療：ALS患者の病気の進行を遅らせ、生存期間を延ばす能力があるため、この薬剤は広く使用
  • タイプ：散発性ALSの信頼できるバイオマーカーを特定するための継続的な研究
  • 治療段階：進行期における生活の質と症状管理の最適化筋萎縮性側索硬化症治療
  • 投与経路：使いやすさと投与スケジュールの柔軟性から経口投与が好まれる傾向が高まっている
  • 流通チャネル：ALS治療の提供における小売薬局の役割の拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 筋萎縮性側索硬化症治療市場：治療別

• イントロダクション
• 薬剤治療
  • デキストロメトルファン/キニジン
  • エダラボン
  • リルゾール
  • トフェルセン
• 治療
  • 遺伝子治療
  • 幹細胞療法

第7章 筋萎縮性側索硬化症治療市場：タイプ別

• イントロダクション
• 家族性ALS
• 散発性ALS

第8章 筋萎縮性側索硬化症治療市場：治療段階別

• イントロダクション
• 進行期治療
• 早期治療
• 中期治療

第9章 筋萎縮性側索硬化症治療市場：投与経路別

• イントロダクション
• 脊髄内
• 静脈内
• 経口

第10章 筋萎縮性側索硬化症治療市場：流通チャネル別

• イントロダクション
• 病院薬局
• 小売薬局

第11章 南北アメリカの筋萎縮性側索硬化症治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の筋萎縮性側索硬化症治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの筋萎縮性側索硬化症治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AB Science SA
• Alector, Inc.
• Amylyx Pharmaceuticals, Inc.
• Apotex Inc.
• Aquestive Therapeutics, Inc.
• Ascend Pharmaceuticals LLC
• AstraEureka Pharmaceuticals
• Biogen Inc.
• BrainStorm Cell Limited
• Cipla Limited
• CorestemChemon Inc.
• Coya Therapeutics, Inc.
• Cytokinetics, Incorporated
• Dewpoint Therapeutics, Inc.
• DR. REDDY'S LABORATORIES LIMITED
• F. Hoffmann-La Roche Ltd
• Genervon Biopharmaceuticals, LLC
• GlaxoSmithKline PLC
• Implicit Bioscience Ltd.
• Ionis Pharmaceuticals, Inc.
• ITF Pharma, Inc.
• Kringle Pharma, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neurimmune AG
• Novartis AG
• ONO PHARMACEUTICAL CO., LTD.
• Orion Corporation
• Orphazyme A/S
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd.
• Treeway B.V.
• Viatris Inc.
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET MULTI-CURRENCY
• FIGURE 2. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET MULTI-LANGUAGE
• FIGURE 3. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 4. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 56. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 57. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 59. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 93. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 94. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 96. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 100. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 101. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 103. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 149. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 155. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 156. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 162. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 163. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 176. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 178. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 185. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 191. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 192. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 199. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 205. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 206. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 212. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 213. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 220. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 221. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 223. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 226. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 227. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 232. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 233. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 234. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 240. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 241. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 246. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 247. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 248. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 249. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 251. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 252. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 253. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 254. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 255. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 256. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 257. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 258. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 259. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 261. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 262. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 268. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 269. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 274. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 275. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 276. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 281. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 282. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 283. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD M

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 688.06 million in 2024 and is projected to grow to USD 733.06 million in 2025, with a CAGR of 6.89%, reaching USD 1,026.61 million by 2030.

The evolving world of amyotrophic lateral sclerosis treatment presents a dynamic interplay of clinical innovation and changing patient needs. In recent times, significant strides have been made to understand the complexity of this debilitating condition. Ongoing research has catalyzed developments that not only extend the duration of quality life but also reframe the overall approach to therapeutic interventions. With a focus on improving patient outcomes and reducing the burden of disease, the market continues to grow as diagnostic capabilities and treatment modalities advance in tandem.

This report provides a comprehensive evaluation of the emerging trends, technological breakthroughs, and strategic market movements that are redefining the treatment paradigm. By drawing on the latest data and a robust analytical framework, the discussion unifies the perspectives of clinicians, researchers, and decision-makers. Ultimately, the narrative unfolds a detailed picture that underscores the importance of innovation and collaborative efforts in the ongoing battle against amyotrophic lateral sclerosis.

Transformative Shifts in the ALS Treatment Landscape

Recent years have witnessed transformative shifts in the landscape of ALS treatment that have redefined traditional paradigms. Innovations in both pharmaceutical and therapeutic approaches have triggered a period of rapid evolution, where novel compounds and avant-garde protocols challenge the status quo. Breakthroughs in gene therapy and stem cell research are paving the way for customized treatment regimens, while improvements in medication formulations have enhanced the efficacy and safety profiles of existing drugs.

Technological advancements have accelerated the pace at which clinical trials and regulatory approvals occur, effectively shortening the gap between discovery and patient access. Additionally, real-world evidence and digital monitoring technologies have started to shape treatment strategies, providing actionable insights into clinical outcomes. These transformative shifts are supported by an increasing willingness among key stakeholders to embrace risk and invest in pioneering treatments. This dynamic environment not only encourages a culture of innovation but also fosters stronger partnerships across the value chain, ultimately setting the stage for a future where personalized medicine plays a central role in managing ALS.

Key Segmentation Insights in ALS Treatment

A deep dive into market segmentation reveals diverse layers of opportunities that drive the ALS treatment ecosystem. Segmentation based on treatment underscores two primary approaches: medication and therapies. Within medications, the analysis extends to specific compounds such as Dextromethorphan/Quinidine, Edaravone, Riluzole, and Tofersen, each offering unique mechanisms of action. On the other hand, therapies are further delineated into gene therapy and stem cell therapy, reflecting a trend towards innovative solutions that target the genetic underpinnings of the disease.

Further segmentation by type differentiates familial ALS from sporadic ALS, highlighting the variations in treatment responsiveness and clinical strategy. The investigation of treatment stage segmentation illustrates a spectrum ranging from early, mid, to advanced stage treatment, thereby allowing a better alignment of therapeutic interventions with disease progression. Analysis based on the route of administration - including intrathecal, intravenous, and oral methods - showcases the adaptation of treatment methods to patient-specific needs and clinical settings. Finally, insights into the distribution channel, examined through the lens of hospital pharmacies versus retail pharmacies, emphasize the evolving strategies in supply chain management that can streamline patient access to these critical therapies.

Based on Treatment, market is studied across Medication and Therapies. The Medication is further studied across Dextromethorphan/Quinidine, Edaravone, Riluzole, and Tofersen. The Therapies is further studied across Gene Therapy and Stem Cell Therapy.

Based on Type, market is studied across Familial ALS and Sporadic ALS.

Based on Treatment Stage, market is studied across Advanced Stage Treatment, Early Stage Treatment, and Mid Stage Treatment.

Based on Route of Administration, market is studied across Intrathecal, Intravenous, and Oral.

Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.

Critical Regional Insights in the ALS Market

An examination of regional dynamics reveals distinct market behaviors and growth trajectories across key territories. In the Americas, the landscape is characterized by robust investment in research and a strong foundation of clinical expertise that continues to fuel advancements in treatment. The region benefits from a well-established healthcare infrastructure that is conducive to rapid clinical integration of newly developed therapies.

In Europe, the Middle East, and Africa, regulatory practices and government policies play an influential role in steering market dynamics. This territory exhibits a unique blend of mature markets interlaced with emerging opportunities, reflecting a balance between traditional practices and innovative treatment modalities. Meanwhile, in the Asia-Pacific region, rapid economic growth and increasing healthcare expenditure are driving significant expansion in treatment adoption. The region's strategic investments in medical research and technology further enhance its competitiveness on the global stage. Together, these insights illuminate the intricate balance between geographical, economic, and regulatory factors that influence the treatment landscape, enabling stakeholders to tailor strategies for regional market penetration and sustained growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Major Companies Advancements in ALS Treatment

The competitive arena of ALS treatment features a broad spectrum of companies that are instrumental in advancing therapeutic innovation. Dominant players in the market, including AB Science SA, Alector, Inc., Amylyx Pharmaceuticals, Inc., and Apotex Inc., are continuously refining their clinical pipelines and fostering collaborative partnerships to accelerate breakthrough therapies. This landscape is enriched by the participation of firms such as Aquestive Therapeutics, Inc., Ascend Pharmaceuticals LLC, and AstraEureka Pharmaceuticals, whose focused efforts in clinical research are paving the way for new treatment protocols.

Key industry leaders like Biogen Inc., BrainStorm Cell Limited, and Cipla Limited, among others, are also playing pivotal roles in enhancing treatment outcomes. Companies such as CorestemChemon Inc., Coya Therapeutics, Inc., and Cytokinetics, Incorporated are emerging as powerhouses by leveraging innovative research approaches and streamlined development processes. Further contributions from Dewpoint Therapeutics, Inc., DR. REDDY'S LABORATORIES LIMITED, and prominent industry giants like F. Hoffmann-La Roche Ltd, Genervon Biopharmaceuticals, LLC, and GlaxoSmithKline PLC continue to influence market dynamics. Each entity, from Ionis Pharmaceuticals, Inc. to Zydus Lifesciences Limited, brings unique expertise and strategic focus that collectively drive forward the cutting edge of ALS treatment options.

The report delves into recent significant developments in the Amyotrophic Lateral Sclerosis Treatment Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, Alector, Inc., Amylyx Pharmaceuticals, Inc., Apotex Inc., Aquestive Therapeutics, Inc., Ascend Pharmaceuticals LLC, AstraEureka Pharmaceuticals, Biogen Inc., BrainStorm Cell Limited, Cipla Limited, CorestemChemon Inc., Coya Therapeutics, Inc., Cytokinetics, Incorporated, Dewpoint Therapeutics, Inc., DR. REDDY'S LABORATORIES LIMITED, F. Hoffmann-La Roche Ltd, Genervon Biopharmaceuticals, LLC, GlaxoSmithKline PLC, Implicit Bioscience Ltd., Ionis Pharmaceuticals, Inc., ITF Pharma, Inc., Kringle Pharma, Inc., Mitsubishi Tanabe Pharma Corporation, Neurimmune AG, Novartis AG, ONO PHARMACEUTICAL CO., LTD., Orion Corporation, Orphazyme A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Treeway B.V., Viatris Inc., and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

For stakeholders eyeing leadership in the ALS treatment market, the insights outlined in this analysis provide a clear roadmap for strategic action. Decision-makers are encouraged to bolster investment in research and development to uncover next-generation therapies that address the multifaceted challenges of disease progression. Embracing a multidisciplinary approach that integrates data analytics, clinical research, and patient-centric strategies is essential for achieving competitive differentiation.

Companies should prioritize the exploration of emerging treatment modalities, such as advanced gene therapies and precision medicine, to enhance therapeutic outcomes. Additionally, a stronger focus on streamlined regulatory pathways and collaborative partnerships at both the regional and global levels can significantly reduce time-to-market for innovative products. Implementing progressive distribution strategies that leverage both hospital and retail channels will further facilitate wider patient access. Ultimately, industry leaders must remain agile, continuously adapting to evolving market conditions while promoting sustainable and scalable growth initiatives that reflect the complex, rapidly shifting treatment landscape.

Conclusion and Strategic Perspective

In summary, the current landscape of ALS treatment is marked by technological breakthroughs, strategic regional investments, and a competitive environment fueled by both legacy and emerging companies. This analysis underscores the importance of a holistic view that encompasses diverse treatment modalities, patient-specific needs, and dynamic market drivers. The comprehensive insights provided here serve to bridge scientific innovation with strategic market implementation, highlighting the necessity for integrated approaches in tackling the challenges associated with amyotrophic lateral sclerosis.

Looking forward, the interplay between innovative research and evolving regional strategies will define the future trajectory of the market. The evolving insights reinforce a commitment to clinical excellence and a collaborative spirit among stakeholders, ensuring that the advancements in treatment are both meaningful and accessible. The synthesis of key findings, transformative shifts, and strategic recommendations encapsulates the forward-thinking mindset required for sustained success in this critical field.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence and rising incidence of amyotrophic lateral sclerosis
    • 5.1.1.2. Increased focus on gene therapy and regenerative medicine as potential avenues for effective ALS treatment
    • 5.1.1.3. Rising establishment of specialized ALS treatment centers and supportive health infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. Limited treatment efficacy concern associated with ALS treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion of clinical trial networks that support faster evaluations and better patient outcomes
    • 5.1.3.2. Supportive public-private source for research initiatives in ALS treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent approval processes for ALS therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Significant usage of the medication owing to their ability to slow disease progression and extend survival in ALS patients
  • 5.2.2. Type: Ongoing research into identifying reliable biomarkers for sporadic ALS
  • 5.2.3. Treatment Stage: Optimizing quality of life and symptom management in advanced-stage amyotrophic lateral sclerosis treatment
  • 5.2.4. Route of Administration: Rising preference for oral administration for its ease of use and flexibility in dosing schedules
  • 5.2.5. Distribution Channel: Expanding role of retail pharmacies in delivering ALS treatments
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

• 6.1. Introduction
• 6.2. Medication
  • 6.2.1. Dextromethorphan/Quinidine
  • 6.2.2. Edaravone
  • 6.2.3. Riluzole
  • 6.2.4. Tofersen
• 6.3. Therapies
  • 6.3.1. Gene Therapy
  • 6.3.2. Stem Cell Therapy

7. Amyotrophic Lateral Sclerosis Treatment Market, by Type

• 7.1. Introduction
• 7.2. Familial ALS
• 7.3. Sporadic ALS

8. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage

• 8.1. Introduction
• 8.2. Advanced Stage Treatment
• 8.3. Early Stage Treatment
• 8.4. Mid Stage Treatment

9. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration

• 9.1. Introduction
• 9.2. Intrathecal
• 9.3. Intravenous
• 9.4. Oral

10. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Retail Pharmacies

11. Americas Amyotrophic Lateral Sclerosis Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Revive Therapeutics enhances ALS treatment prospects with DiagnaMed molecular hydrogen IP acquisition LOI
  • 14.3.2. Woolsey secures extended series B funding to advance ALS treatment
  • 14.3.3. LifeArc partnership with Neuropeutics Inc. for advance ALS therapy development
  • 14.3.4. FDA lifts clinical hold on Phase 1 trial of AMX0114's safety and biomarker evaluation in ALS treatment
  • 14.3.5. Alchemab Therapeutics and Lilly partner to pioneer novel ALS therapies
  • 14.3.6. Dewpoint and Mitsubishi Tanabe forge USD 480M partnership to advance ALS therapy
  • 14.3.7. Eisai launches Rozebalamin for injection 25 mg for ALS treatment in Japan
  • 14.3.8. Verge Genomics collaborates with Lilly to enhance development of novel ALS treatments
  • 14.3.9. Leal Therapeutics secures USD 45 million in funding to advance LTX-002 ALS therapy
  • 14.3.10. NLS Pharmaceutics and Kadimastem enter a strategic merger to accelerate ALS treatment innovation
  • 14.3.11. NeuroSense seeks early commercialization approval for ALS treatment in Canada
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Mitsubishi Tanabe Pharma Corporation
  • 14.4.2. Amylyx Pharmaceuticals Inc.
  • 14.4.3. Ionis Pharmaceuticals, Inc.
  • 14.4.4. Aquestive Therapeutics Inc.

Companies Mentioned

• 1. AB Science SA
• 2. Alector, Inc.
• 3. Amylyx Pharmaceuticals, Inc.
• 4. Apotex Inc.
• 5. Aquestive Therapeutics, Inc.
• 6. Ascend Pharmaceuticals LLC
• 7. AstraEureka Pharmaceuticals
• 8. Biogen Inc.
• 9. BrainStorm Cell Limited
• 10. Cipla Limited
• 11. CorestemChemon Inc.
• 12. Coya Therapeutics, Inc.
• 13. Cytokinetics, Incorporated
• 14. Dewpoint Therapeutics, Inc.
• 15. DR. REDDY'S LABORATORIES LIMITED
• 16. F. Hoffmann-La Roche Ltd
• 17. Genervon Biopharmaceuticals, LLC
• 18. GlaxoSmithKline PLC
• 19. Implicit Bioscience Ltd.
• 20. Ionis Pharmaceuticals, Inc.
• 21. ITF Pharma, Inc.
• 22. Kringle Pharma, Inc.
• 23. Mitsubishi Tanabe Pharma Corporation
• 24. Neurimmune AG
• 25. Novartis AG
• 26. ONO PHARMACEUTICAL CO., LTD.
• 27. Orion Corporation
• 28. Orphazyme A/S
• 29. Otsuka Pharmaceutical Co., Ltd.
• 30. Pfizer, Inc.
• 31. Sanofi SA
• 32. Sun Pharmaceutical Industries Ltd
• 33. Teva Pharmaceutical Industries Ltd.
• 34. Treeway B.V.
• 35. Viatris Inc.
• 36. Zydus Lifesciences Limited